Evidence map›Paper›PMID 42118679›Full record

ReviewFEBS open bio2026

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection.

Xuying Yin, Dangsheng Xiao, Jiezuan Yang

Abstract readReview
In one paragraph

Review in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xuying YinDepartment of Nursing, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dangsheng XiaoZhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases, Department of Geriatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiezuan YangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Infectious Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0002-0928-2388

Funding

Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project 2023ZL482
6 · The paper itself

Abstract

Chemokines and their cognate receptors are central orchestrators of the immune response to Mycobacterium tuberculosis (Mtb) infection. While their overall significance in tuberculosis (TB) is well-established, this review synthesizes recent advances to clarify the distinct roles of CC and CXC chemokines in differentiating active disease, latent infection, and the often overlooked subclinical TB state. We evaluate the potential of specific chemokine signatures as emerging diagnostic biomarkers compared to conventional standards and assess their promise as novel therapeutic targets in personalized clinical settings. Furthermore, we examine paradoxical findings in the field, including how certain chemokines (such as CCL5, CXCL12, and CXCL16) can simultaneously support host defense and facilitate pathogen evasion. By integrating these complex narratives, we offer a renewed perspective on chemokine dynamics in TB immunity, bridge important gaps between bench research and clinical application, and establish a strong foundation for developing precision diagnostics and host-directed therapies.

Indexed as

Chemokines, CCChemokines, CXCMycobacterium tuberculosisTuberculosisAnimalsBiomarkersHumansReceptors, ChemokineBiomarkersChemokines, CCChemokines, CXCReceptors, Chemokinebiomarkerschemokinesimmune regulationMycobacterium tuberculosistherapeutic targets

Identifiers

PMID42118679
PMCPMC13327060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.